Inotek slashes share price ahead of IPO

The biotech IPO window has remained open during the first quarter of the year, but not all upstart drug developers are finding it easy to make the leap into the public market. Lexington, MA-based Inotek joined the list of the under-performers, opting to slash its share price from a range of $13 to $15 to a mere $6 a share. Now it expects to raise about $40 million from the sale of 6.7 million shares. And it should emerge with a market cap of under $100 million. The biotech, developing a glaucoma therapy, also raised $20 million in debt financing, according to an SEC filing. Filing

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.